Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Trial ID: NCT03080974

Interventional - Phase 2 - Recruiting

Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.

Conditions

• Pancreatic Adenocarcinoma

Interventions

• Nivolumab
• Irreversible Electroporation

Eligibility

Inclusion criteria

• ≥ 18 years if age
• Diagnosed with stage III pancreatic cancer
• Tumor is measurable
• Glomerular Filtration Rate \> 60 m/L/min/1.73 m(2)
• Willing and able to comply with the protocol requirements
• Able to comprehend and have signed the informed consent to participate

Exclusion criteria

• Participating in another clinical trial for the treatment of cancer at time of screening
• Are pregnant or currently breast feeding
• Have a cardiac pacemaker or Implantable Cardioverter Defibrillator implanted that cannot be deactivated during the procedure
• Have non-removable implants with metal parts within 1 cm of the target lesion
• Had a myocardial infarction within 3 months prior to enrollment

Sponsor

University of Louisville

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows